Israel’s ImmunoBrain Checkpoint (see here previously) has been awarded a grant of $5 million over 3 years to support human clinical trials of IBC-Ab002, for the treatment of Alzheimer’s disease. Development was based on Weizmann Institute immune system studies. https://www.weizmann-usa.org/news-media/in-the-news/immunobrain-checkpoint-awarded-5-million-us-nia-grant-for-phase-1b-alzheimer-s-disease/

Israel’s ImmunoBrain Checkpoint aims to begin trials of its IBC-Ab002 treatment for Alzheimer’s disease. The antibody, developed by its Chief Scientist EMET Prize-winning Weizmann Institute Professor Michal Schwartz, boosts the immune system to induce brain repair processes. https://www.jpost.com/health-science/israeli-revolutionary-alzheimers-treatment-to-launch-phase-1-trial-641848 https://www.ibcheckpoint.com/